ID: ALA324290

Max Phase: Preclinical

Molecular Formula: C16H17NO2

Molecular Weight: 255.32

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1cc(/C=C/c2ccc(N)cc2)cc(OC)c1

Standard InChI:  InChI=1S/C16H17NO2/c1-18-15-9-13(10-16(11-15)19-2)4-3-12-5-7-14(17)8-6-12/h3-11H,17H2,1-2H3/b4-3+

Standard InChI Key:  LGVZJSLFOMGJOS-ONEGZZNKSA-N

Associated Targets(Human)

HL-60 67320 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Cytochrome P450 19A1 6099 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Quinone reductase 2 885 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HT-29 80576 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Caco-2 12174 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Mus musculus 284745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Serum 598 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 255.32Molecular Weight (Monoisotopic): 255.1259AlogP: 3.46#Rotatable Bonds: 4
Polar Surface Area: 44.48Molecular Species: NEUTRALHBA: 3HBD: 1
#RO5 Violations: 0HBA (Lipinski): 3HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 3.99CX LogP: 3.17CX LogD: 3.17
Aromatic Rings: 2Heavy Atoms: 19QED Weighted: 0.67Np Likeness Score: 0.09

References

1. Roberti M, Pizzirani D, Simoni D, Rondanin R, Baruchello R, Bonora C, Buscemi F, Grimaudo S, Tolomeo M..  (2003)  Synthesis and biological evaluation of resveratrol and analogues as apoptosis-inducing agents.,  46  (16): [PMID:12877593] [10.1021/jm030785u]
2. Liu H, Dong A, Gao C, Tan C, Liu H, Zu X, Jiang Y..  (2008)  The design, synthesis, and anti-tumor mechanism study of N-phosphoryl amino acid modified resveratrol analogues.,  16  (23): [PMID:18952444] [10.1016/j.bmc.2008.10.022]
3. Sun B, Hoshino J, Jermihov K, Marler L, Pezzuto JM, Mesecar AD, Cushman M..  (2010)  Design, synthesis, and biological evaluation of resveratrol analogues as aromatase and quinone reductase 2 inhibitors for chemoprevention of cancer.,  18  (14): [PMID:20558073] [10.1016/j.bmc.2010.05.042]
4. Paul S, Mizuno CS, Lee HJ, Zheng X, Chajkowisk S, Rimoldi JM, Conney A, Suh N, Rimando AM..  (2010)  In vitro and in vivo studies on stilbene analogs as potential treatment agents for colon cancer.,  45  (9): [PMID:20627379] [10.1016/j.ejmech.2010.05.019]
5. Uzura S, Sekine-Suzuki E, Nakanishi I, Sonoda M, Tanimori S..  (2016)  A facile and rapid access to resveratrol derivatives and their radioprotective activity.,  26  (16): [PMID:27426305] [10.1016/j.bmcl.2016.07.018]

Source